

# e-Therapeutics plc

16:02 07 Oct 2019

## E-Therapeutics making good progress says chief executive

E-Therapeutics PLC (LON:ETX) says multiple proposals for its artificial intelligence-based drug research products have been sent to potential partners and customers.

The AIM-listed group has programmes running already using its network-driven drug discovery (NDD) platform and Genome Associated Interaction Networks (GAINs) with Danish pharma Novo Nordisk for type-2 diabetes.

Watch the interview: e-Therapeutics continuing to convert business development into cash generating partnerships

In August, it also announced a collaboration with an unnamed pharma major for a project looking at brain conditions such as Parkinson's, Alzheimer's and Huntington's.

E-Therapeutics added that these collaborations have been structured so that it retains ownership of key data while enabling the output from its platforms to be tested in its partners' in-house assays.

"We continue to believe that the best way to create significant incremental value is to generate proprietary pre-clinical data, particularly on our in-house novel therapeutic assets.

"In particular, we think that there is an exciting opportunity to develop our own datasets in other core disease areas using our new GAINs approach.

"In addition, as noted, we have also created detailed plans on the experiments we would do next on our existing portfolio of pre-clinical assets, particularly in the immuno-oncology space."

E-Therapeutics added it is also looking at alternative sources of funding, including 'shared funding' approaches.

Results for the six months to July showed efforts to pare down on costs paying off as operating losses dropped to £1.6m (€2.8m) with cash at the period end of £5.2m (€5.9m).


Ray Barlow, chief executive, said: "The business has continued to make good progress over the past six months and is continuing to convert the extensive work done in business development into a range of potential revenue and cash-generating partnerships."

--Edited to add video link

**Price:** 3.65

**Market Cap:** £9.82 m

### 1 Year Share Price Graph



January 2019 August 2019 January 2020

### Share Information

**Code:** ETX

**Listing:** AIM

**52 week High Low**  
5.5 1.25

**Sector:** Pharma & Biotech

**Website:** [www.etherapeutics.co.uk](http://www.etherapeutics.co.uk)

### Company Synopsis:

*We are an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology. &nbsp;*

*Our novel methodology and our Discovery Engine allow us to discover new and better drugs in a more efficient and effective way.*

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts

journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).